PGD for all cystic fibrosis carrier couples: novel strategy for preventive medicine and cost analysis.
Over 1000 children affected with cystic fibrosis (CF) are born annually in the USA. Since IVF with preimplantation genetic diagnosis (PGD) is an alternative to raising a sick child or to aborting an affected fetus, a cost-benefit analysis was performed for a national IVF-PGD program for preventing CF. The amount spent to deliver healthy children for all CF carrier-couples by IVF-PGD was compared with the average annual and lifetime direct medical costs per CF patient avoided. Treating annually about 4000 CF carrier-couples with IVF-PGD would result in 3715 deliveries of non-affected children at a cost of $57,467 per baby. Because the average annual direct medical cost per CF patient was $63,127 and life expectancy is 37 years, savings would be $2.3 million per patient and $2.2 billion for all new CF patients annually in lifetime treatment costs. Cumulated net saving of an IVF-PGD program for all carrier-couples for 37 years would be $33.3 billion. A total of 618,714 cumulative years of patients suffering because of CF and thousands of abortions could be prevented. A national IVF-PGD program is a highly cost-effective novel modality of preventive medicine and would avoid most births of individuals affected with debilitating genetic disease.
Tur-Kaspa
I
I
Institute for Human Reproduction (IHR), 2825 N Halsted St., Chicago, IL 60657, USA. DrTK@infertilityIHR.com
Aljadeff
G
G
Rechitsky
S
S
Grotjan
H E
HE
Verlinsky
Y
Y
D003365:Costs and Cost Analysis; D003550:Cystic Fibrosis / Q000235:genetics*; D005260:Female; D006580:Genetic Carrier Screening; D006801:Humans; D008297:Male; D019836:Preimplantation Diagnosis; D011315:Preventive Medicine